VJHemOnc is committed to improving our service to you

ICML 2019 | Intratumoral CpG, ibrutinib and radiotherapy in low-grade R/R follicular lymphoma

VJHemOnc is committed to improving our service to you

Tanaya Shree

Tanaya Shree, MD, Stanford University Medical Center, California, CA, discusses the interim clinical and correlative results of the Phase I/II trial of the CpG TLR9 agonist SD-101, ibrutinib and radiation therapy in relapsed/refractory low-grade follicular lymphoma (NCT02927964). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter